Tearsheet

Covista (CVSA)


Market Price (6/17/2026): $117.75 | Market Cap: $4.0 BilSector: Consumer Discretionary | Industry: Education Services

Covista (CVSA)


Market Price (6/17/2026): $117.75
Market Cap: $4.0 Bil
Sector: Consumer Discretionary
Industry: Education Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.8%, FCF Yield is 8.3%

Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 19%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18%

Low stock price volatility
Vol 12M is 47%

Megatrend and thematic drivers
Megatrends include Cybersecurity. Themes include Software Security, Network Security, and Cloud Security.

Key risks
CVSA key risks include [1] decelerating revenue growth and [2] a periodic lag in operating cash flow versus operating profit.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.8%, FCF Yield is 8.3%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 19%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18%
3 Low stock price volatility
Vol 12M is 47%
4 Megatrend and thematic drivers
Megatrends include Cybersecurity. Themes include Software Security, Network Security, and Cloud Security.
5 Key risks
CVSA key risks include [1] decelerating revenue growth and [2] a periodic lag in operating cash flow versus operating profit.

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 6/15/2026

Covista (CVSA) stock has gained about 20% since 2/28/2026 because of the following key factors:

1. Strong Fiscal Q3 2026 Earnings Beat and Raised Full-Year Guidance.

Covista reported robust financial results for its fiscal Q3 2026 (ended February 28, 2026) on May 7, 2026, exceeding analyst expectations. The company announced revenue of $487 million, beating estimates by 2.7%, and adjusted earnings per share (EPS) of $1.98, a 14.9% beat against consensus estimates. Adjusted EBITDA also surpassed expectations by 8.6%, reaching $127.9 million. Following this strong performance, management increased its full-year fiscal 2026 revenue guidance to $1.94 billion at the midpoint (from $1.92 billion) and raised adjusted EPS guidance to $8.05 at the midpoint, representing a 1.9% increase. Furthermore, the free cash flow margin significantly improved to 69.1% from 42.4% year-over-year.

2. Strategic Expansion into AI and Healthcare Education.

Covista demonstrated a forward-looking strategy through significant initiatives in healthcare education. On April 14, 2026, the company announced a partnership with Google Cloud to develop an "AI-Powered Classroom of the Future," integrating artificial intelligence into its healthcare education curriculum. Additionally, Chamberlain University, a key institution under Covista, plans to open a new campus in Cincinnati, accepting applications for the Fall 2026 semester. This expansion aims to address the considerable healthcare workforce shortages in Ohio and signals continued growth in Covista's core educational services.

Show more
Updated on 6/15/2026

Covista (CVSA) stock has gained about 20% since 2/28/2026 because of the following key factors:

1. Strong Fiscal Q3 2026 Earnings Beat and Raised Full-Year Guidance.

Covista reported robust financial results for its fiscal Q3 2026 (ended February 28, 2026) on May 7, 2026, exceeding analyst expectations. The company announced revenue of $487 million, beating estimates by 2.7%, and adjusted earnings per share (EPS) of $1.98, a 14.9% beat against consensus estimates. Adjusted EBITDA also surpassed expectations by 8.6%, reaching $127.9 million. Following this strong performance, management increased its full-year fiscal 2026 revenue guidance to $1.94 billion at the midpoint (from $1.92 billion) and raised adjusted EPS guidance to $8.05 at the midpoint, representing a 1.9% increase. Furthermore, the free cash flow margin significantly improved to 69.1% from 42.4% year-over-year.

2. Strategic Expansion into AI and Healthcare Education.

Covista demonstrated a forward-looking strategy through significant initiatives in healthcare education. On April 14, 2026, the company announced a partnership with Google Cloud to develop an "AI-Powered Classroom of the Future," integrating artificial intelligence into its healthcare education curriculum. Additionally, Chamberlain University, a key institution under Covista, plans to open a new campus in Cincinnati, accepting applications for the Fall 2026 semester. This expansion aims to address the considerable healthcare workforce shortages in Ohio and signals continued growth in Covista's core educational services.

3. Positive Analyst Sentiment and Upgraded Price Targets.

The company benefited from a favorable outlook from Wall Street analysts, contributing to investor confidence. As of June 2026, analysts maintained a "Moderate Buy" consensus rating for CVSA. The average twelve-month price target for the stock stood at $155.00, suggesting a potential upside of 20.88% from its price of $128.23 as of June 13, 2026. Specifically, Barrington Research reiterated an "Outperform" rating for Covista with a price target of $170 following the robust fiscal Q3 2026 earnings report.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 20.3% change in CVSA stock from 2/28/2026 to 6/16/2026 was primarily driven by a 24.9% change in the company's P/E Multiple.
(LTM values as of)22820266162026Change
Stock Price ($)98.00117.8920.3%
Change Contribution By: 
Total Revenues ($ Mil)1,8891,9101.1%
Net Income Margin (%)13.4%12.3%-8.6%
P/E Multiple13.817.324.9%
Shares Outstanding (Mil)36344.2%
Cumulative Contribution20.3%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 6/16/2026
ReturnCorrelation
CVSA20.3% 
Market (SPY)9.7%-0.1%
Sector (XLY)1.6%-3.1%

Fundamental Drivers

The 27.4% change in CVSA stock from 11/30/2025 to 6/16/2026 was primarily driven by a 30.6% change in the company's P/E Multiple.
(LTM values as of)113020256162026Change
Stock Price ($)92.56117.8927.4%
Change Contribution By: 
Total Revenues ($ Mil)1,8331,9104.2%
Net Income Margin (%)13.8%12.3%-11.1%
P/E Multiple13.217.330.6%
Shares Outstanding (Mil)36345.3%
Cumulative Contribution27.4%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 6/16/2026
ReturnCorrelation
CVSA27.4% 
Market (SPY)10.4%4.2%
Sector (XLY)0.6%4.5%

Fundamental Drivers

The -10.7% change in CVSA stock from 5/31/2025 to 6/16/2026 was primarily driven by a -18.2% change in the company's P/E Multiple.
(LTM values as of)53120256162026Change
Stock Price ($)132.03117.89-10.7%
Change Contribution By: 
Total Revenues ($ Mil)1,7411,9109.7%
Net Income Margin (%)13.3%12.3%-8.1%
P/E Multiple21.117.3-18.2%
Shares Outstanding (Mil)37348.3%
Cumulative Contribution-10.7%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2025 to 6/16/2026
ReturnCorrelation
CVSA-10.7% 
Market (SPY)28.8%6.8%
Sector (XLY)11.7%1.5%

Fundamental Drivers

The 184.1% change in CVSA stock from 5/31/2023 to 6/16/2026 was primarily driven by a 127.7% change in the company's Net Income Margin (%).
(LTM values as of)53120236162026Change
Stock Price ($)41.50117.89184.1%
Change Contribution By: 
Total Revenues ($ Mil)1,4471,91032.0%
Net Income Margin (%)5.4%12.3%127.7%
P/E Multiple24.117.3-28.2%
Shares Outstanding (Mil)453431.6%
Cumulative Contribution184.1%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2023 to 6/16/2026
ReturnCorrelation
CVSA184.1% 
Market (SPY)86.6%26.4%
Sector (XLY)60.1%23.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
CVSA Return-13%20%66%54%14%14%247%
Peers Return-7%-2%32%58%30%12%177%
S&P 500 Return27%-19%24%23%16%10%101%

Monthly Win Rates [3]
CVSA Win Rate58%42%75%50%50%50% 
Peers Win Rate45%48%60%52%63%53% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
CVSA Max Drawdown-34%-38%-23%-27%-42%-24% 
Peers Max Drawdown-38%-36%-32%-24%-27%-18% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: LOPE, STRA, APEI, UTI, LAUR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/16/2026 (YTD)

How Low Can It Go

EventCVSAS&P 500
2025 US Tariff Shock
  % Loss-15.6%-18.8%
  % Gain to Breakeven18.5%23.1%
  Time to Breakeven37 days79 days
2023 SVB Regional Banking Crisis
  % Loss-18.4%-6.7%
  % Gain to Breakeven22.5%7.1%
  Time to Breakeven14 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-35.6%-24.5%
  % Gain to Breakeven55.3%32.4%
  Time to Breakeven37 days427 days
2020 COVID-19 Crash
  % Loss-37.5%-33.7%
  % Gain to Breakeven60.1%50.9%
  Time to Breakeven51 days140 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-38.9%-12.2%
  % Gain to Breakeven63.7%13.9%
  Time to Breakeven272 days62 days
2014-2016 Oil Price Collapse
  % Loss-59.9%-6.8%
  % Gain to Breakeven149.5%7.3%
  Time to Breakeven663 days15 days

Compare to LOPE, STRA, APEI, UTI, LAUR

In The Past

Covista's stock fell -15.6% during the 2025 US Tariff Shock. Such a loss loss requires a 18.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventCVSAS&P 500
2022 Inflation Shock & Fed Tightening
  % Loss-35.6%-24.5%
  % Gain to Breakeven55.3%32.4%
  Time to Breakeven37 days427 days
2020 COVID-19 Crash
  % Loss-37.5%-33.7%
  % Gain to Breakeven60.1%50.9%
  Time to Breakeven51 days140 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-38.9%-12.2%
  % Gain to Breakeven63.7%13.9%
  Time to Breakeven272 days62 days
2014-2016 Oil Price Collapse
  % Loss-59.9%-6.8%
  % Gain to Breakeven149.5%7.3%
  Time to Breakeven663 days15 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-46.6%-17.9%
  % Gain to Breakeven87.4%21.8%
  Time to Breakeven4491 days123 days
2010 Eurozone Sovereign Debt Crisis / Flash Crash
  % Loss-24.6%-15.4%
  % Gain to Breakeven32.7%18.2%
  Time to Breakeven382 days125 days
2008-2009 Global Financial Crisis
  % Loss-26.1%-53.4%
  % Gain to Breakeven35.3%114.4%
  Time to Breakeven46 days1085 days

Compare to LOPE, STRA, APEI, UTI, LAUR

In The Past

Covista's stock fell -15.6% during the 2025 US Tariff Shock. Such a loss loss requires a 18.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Covista (CVSA)

Adtalem Global Education Inc. provides workforce solutions worldwide. It operates through two segments, Medical and Healthcare; and Financial Services. The Medical and Healthcare segment offers degree and non-degree programs in the medical and healthcare postsecondary education industry. This segment operates Chamberlain University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The Financial Services segment provides test preparation, certifications, conferences, seminars, memberships, and subscriptions to business professionals in the areas of accounting, anti-money laundering, banking, and mortgage lending. It operates Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, OnCourse Learning, and EduPristine. The company was formerly known as DeVry Education Group Inc. and changed its name to Adtalem Global Education Inc. in May 2017. Adtalem Global Education Inc. was incorporated in 1987 and is based in Chicago, Illinois.

AI Analysis | Feedback

1. It's like Kaplan Education, but also owns and operates its own medical, nursing, and veterinary universities.

2. Think of it as a more diversified Strategic Education, Inc. (which owns Strayer and Capella Universities), specializing in healthcare degrees and financial professional certifications.

AI Analysis | Feedback

null

AI Analysis | Feedback

Adtalem Global Education Inc. (symbol: CVSA) primarily sells its services to individuals.

Its major customer categories are:

  1. Students pursuing higher education degrees: This includes individuals enrolled in undergraduate and graduate programs in medicine, nursing, and veterinary medicine through institutions like Chamberlain University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.
  2. Business professionals seeking certifications and continuing education: This category encompasses individuals in fields such as accounting, anti-money laundering, banking, and mortgage lending who utilize services for test preparation, professional certifications, conferences, and ongoing education from brands like Becker Professional Education, Association of Certified Anti-Money Laundering Specialists (ACAMS), and OnCourse Learning.

AI Analysis | Feedback

null

AI Analysis | Feedback

Steve Beard, Chairman and Chief Executive Officer

Steve Beard was named CEO of Covista in 2021 and elected Chairman of the Board in 2024. Under his leadership, Covista transformed from a diversified education and training company to one centered on healthcare education. He joined the company in 2018 as General Counsel and later became Chief Operating Officer, where he led the now divested financial services segment and portfolio repositioning. Prior to Covista, Beard served as Executive Vice President and Chief Administrative Officer at Heidrick & Struggles International. He also serves as board chair of A Better Chicago, a venture philanthropy.

Bob Phelan, Senior Vice President and Chief Financial Officer

Bob Phelan serves as chief financial officer at Covista, bringing over 35 years of finance and operational experience. He oversees all aspects of finance, including real estate and cybersecurity. Since joining Covista in February 2020, Phelan has held multiple leadership roles, including vice president and chief accounting officer, where he managed enterprise-wide accounting and reporting, SEC and regulatory filings, real estate, and strategic sourcing operations.

Michael Betz, Chief Digital Officer and President, Walden University

Michael Betz serves as chief digital officer of Covista and president of Walden University. In his dual role, Betz leads digital transformation and AI strategy across Covista and its institutions. As president of Walden University, he leads the institution, serving over 50,000 online learners through various degree and certificate programs.

Scott Liles, President, Medical and Veterinary

Scott Liles serves as president of the medical and veterinary segment at Covista. He is responsible for leading the growth strategy and operations for institutions such as American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. His leadership focuses on expanding access to medical and veterinary education for students.

Douglas Beck, Senior Vice President, Institutional Support Services, General Counsel and Corporate Secretary

Douglas Beck holds the titles of Senior Vice President, Institutional Support Services, General Counsel, and Corporate Secretary at Covista.

AI Analysis | Feedback

The key risks to Covista's business include:

  1. Heavy reliance on Title IV funding and regulatory changes: Covista's business is significantly dependent on federal funding through Title IV, with some of its institutions nearing a concerning threshold of revenue derived from this source. Changes in government regulations regarding federal student aid could therefore pose a substantial risk to the company's financial stability.
  2. Short-term headwinds at Chamberlain University: The company has experienced short-term challenges, particularly an enrollment decline of 1% at Chamberlain University. These headwinds have contributed to a significant drop in the company's stock value, despite overall revenue growth in other segments like Walden University.

AI Analysis | Feedback

null

AI Analysis | Feedback

Covista (trading under the symbol CVSA), formerly known as Adtalem Global Education Inc. until February 2026, primarily operates in the healthcare education sector, addressing the U.S. healthcare workforce shortage through its various institutions. The company's main products and services include degree and non-degree programs in nursing, health professions, medical, and veterinary postsecondary education. The addressable markets for these services are substantial within the United States.

Addressable Markets for Covista's Main Products and Services (U.S. Region):

  • U.S. Healthcare Education Market: The overall U.S. healthcare education market was estimated at USD 39.24 billion in 2023 and is projected to grow to USD 61.44 billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 9.4%. North America, with the U.S. as a leading contributor, holds the largest share of the global healthcare education market.
  • U.S. Nursing Education Market: This market was valued at USD 9.7 billion in 2024 and is expected to grow at a CAGR of 5.3% between 2025 and 2034. Other estimates place the market size to increase by USD 25.25 billion with a CAGR of 6.1% from 2025 to 2030, and project it to be worth USD 14.57 billion by 2030. North America accounts for approximately 60% of the global nursing education market.
  • U.S. Medical Education Market: The medical education market in the U.S. was valued at USD 35.07 billion in 2024 and is anticipated to reach USD 53.02 billion by 2033, growing at a CAGR of 4.7%. The U.S. continuing medical education (CME) segment alone was valued at USD 3.35 billion in 2024 and is expected to reach USD 4.67 billion by 2030.
  • U.S. Veterinary Education Market: The U.S. veterinary education market was estimated at USD 754.4 million in 2024. It is projected to grow at a CAGR of 7.62% from 2025 to 2030, reaching USD 1.16 billion by 2030. Another report valued the U.S. market at USD 1.01 billion in 2024, with a projected increase to USD 1.56 billion by 2032.
  • U.S. Healthcare Workforce Management System Market: Given Covista's focus on addressing workforce shortages, the U.S. healthcare workforce management system market is also relevant. This market generated USD 662.8 million in revenue in 2023 and is expected to reach USD 1,513.5 million by 2030, with a CAGR of 12.5% from 2024 to 2030. Another estimate for the U.S. market is USD 0.92 billion in 2025, projected to reach USD 2.51 billion by 2035 with a CAGR of 10.68%.

AI Analysis | Feedback

Covista (CVSA) is strategically positioned to leverage several key drivers for future revenue growth over the next 2-3 years, primarily by addressing the persistent demand within the healthcare sector.

  1. Sustained Enrollment Growth in Healthcare Programs: As America's largest healthcare educator, Covista benefits from the ongoing shortage of healthcare workers, which fuels demand for its educational programs. The company has demonstrated consistent enrollment growth across its institutions, including Chamberlain University and Walden University, with total enrollment increasing year-over-year. This continued growth in its student base directly translates to increased revenue.
  2. Expansion of Healthcare Education Offerings and Geographic Reach (Platform Extension): Covista's "Purpose at Scale" growth strategy includes platform extension, focusing on serving more students in additional communities and expanding into new, adjacent healthcare domains where workforce shortages are most acute. This strategic expansion aims to capture a larger share of the healthcare education market.
  3. Scaling Employer Partnerships and Integration: A crucial aspect of Covista's growth plan is to enhance and scale its partnerships with employers. By connecting educational pathways more directly to employer needs and integrating with healthcare systems, Covista aims to better address workforce demands, which can lead to increased program relevance, higher enrollment, and new revenue streams through corporate training or customized programs.
  4. Leveraging Technology and AI in Education: Covista is integrating technology and artificial intelligence (AI) into its educational offerings. This includes partnerships with AI programs like HelloAI, Google Cloud, and Hippocratic AI to train healthcare professionals in AI-powered decision-making and prepare them for evolving industry demands. This focus on tech-enabled education is intended to catalyze enrollments, provide a competitive edge, and ensure graduates are well-prepared for the future healthcare landscape.

AI Analysis | Feedback

Share Repurchases

  • The company completed a $150 million share repurchase program and authorized a new program of up to $750 million, set to run through December 2028.
  • Since February 2022, Covista (as Adtalem Global Education) has repurchased $913 million worth of shares, reducing outstanding shares by 30%.
  • In the second quarter of fiscal year 2026, $165 million was deployed to repurchase 1.7 million shares at an average price of $95, completing the prior $150 million authorization and leaving $728 million remaining on the $750 million authorization as of December 31, 2025.

Capital Expenditures

  • Capital expenditures were approximately $39.88 million in fiscal year 2021, $31.05 million in fiscal year 2022, and $26.01 million in fiscal year 2023.
  • In fiscal year 2024, capital expenditures were approximately $48.89 million, increasing to $50.33 million in fiscal year 2025.
  • For the twelve months ending December 2025, capital expenditures amounted to approximately $59.88 million, with future expenditures expected to focus on campus investments and capacity expansion.

Better Bets vs. Covista (CVSA)

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

CVSALOPESTRAAPEIUTILAURMedian
NameCovista Grand Ca.Strategi.American.Universa.Laureate. 
Mkt Price117.89144.3975.2751.8938.4535.7463.58
Mkt Cap4.03.91.60.92.15.13.0
Rev LTM1,9101,1261,2716598691,7381,198
Op Inc LTM3703111986255417254
FCF LTM336260174741264217
FCF 3Y Avg2892381385235217177
CFO LTM4062942188882370256
CFO 3Y Avg3412771796981295228

Growth & Margins

CVSALOPESTRAAPEIUTILAURMedian
NameCovista Grand Ca.Strategi.American.Universa.Laureate. 
Rev Chg LTM9.7%7.4%3.0%3.8%11.0%13.8%8.6%
Rev Chg 3Y Avg9.7%7.1%6.2%3.1%21.2%10.9%8.4%
Rev Chg Q4.5%6.7%0.8%6.2%6.7%15.4%6.5%
QoQ Delta Rev Chg LTM1.1%1.8%0.2%1.6%1.6%2.1%1.6%
Op Inc Chg LTM8.9%10.7%21.1%38.1%-29.1%19.2%14.9%
Op Inc Chg 3Y Avg18.4%9.8%54.5%1,751.3%71.6%14.9%36.4%
Op Mgn LTM19.4%27.6%15.6%9.4%6.3%24.0%17.5%
Op Mgn 3Y Avg17.9%26.9%13.7%7.2%7.2%23.1%15.8%
QoQ Delta Op Mgn LTM-0.2%0.2%0.1%1.1%-2.0%-1.4%-0.0%
CFO/Rev LTM21.3%26.1%17.2%13.4%9.5%21.3%19.2%
CFO/Rev 3Y Avg19.6%26.4%14.6%10.8%10.4%18.4%16.5%
FCF/Rev LTM17.6%23.1%13.7%11.2%0.1%15.2%14.4%
FCF/Rev 3Y Avg16.6%22.6%11.2%8.2%4.7%13.6%12.4%

Valuation

CVSALOPESTRAAPEIUTILAURMedian
NameCovista Grand Ca.Strategi.American.Universa.Laureate. 
Mkt Cap4.03.91.60.92.15.13.0
P/S2.13.41.31.42.42.92.3
P/Op Inc10.912.48.215.438.412.212.3
P/EBIT11.012.38.217.034.812.612.5
P/E17.317.612.523.549.618.217.9
P/CFO10.013.17.510.725.713.711.9
Total Yield5.8%5.7%11.4%4.3%2.0%5.5%5.6%
Dividend Yield0.0%0.0%3.5%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg9.4%5.3%6.9%11.2%3.0%6.7%6.8%
D/E0.20.00.10.20.10.10.1
Net D/E0.1-0.0-0.0-0.10.10.10.0

Returns

CVSALOPESTRAAPEIUTILAURMedian
NameCovista Grand Ca.Strategi.American.Universa.Laureate. 
1M Rtn-4.1%-8.5%-3.7%-2.7%-2.8%11.3%-3.3%
3M Rtn10.5%-13.9%-5.8%-7.3%2.7%4.4%-1.5%
6M Rtn17.5%-12.6%-5.6%38.2%48.4%6.5%12.0%
12M Rtn-4.4%-22.7%-7.7%89.5%14.3%59.6%5.0%
3Y Rtn203.5%40.2%9.0%1,171.8%498.9%220.3%211.9%
1M Excs Rtn-5.5%-9.9%-5.1%-4.1%-4.2%9.9%-4.7%
3M Excs Rtn-1.3%-25.7%-17.7%-19.1%-9.1%-7.5%-13.4%
6M Excs Rtn16.9%-18.0%-15.4%30.5%44.8%1.2%9.0%
12M Excs Rtn-28.9%-47.6%-33.3%62.1%-11.2%35.9%-20.0%
3Y Excs Rtn106.4%-38.4%-67.4%931.7%389.9%133.3%119.8%

Comparison Analyses

null

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA021658  ALVESCOciclesonideaerosol, metered1102008-11.8%-4.2%-0.4%0.0%124.4%
Collapse to Preview
Post-Approval Fwd Returns
FDA
App #
Brand
Name
Generic
Name
Dosage
Form
FDA
Approval
3M
Rtn
6M
Rtn
1Y
Rtn
2Y
Rtn
Total
Rtn
NDA021658  ALVESCOciclesonideaerosol, metered1102008-11.8%-4.2%-0.4%0.0%124.4%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Chamberlain726634571558564
Walden693595534485 
Medical and Veterinary369356346339343
Total1,7881,5851,4511,382907


Operating Income by Segment
$ Mil20252024202320222021
Walden184131110105 
Chamberlain153138136127129
Medical and Veterinary6972676968
Litigation reserve6-18-100 
Business integration expense0-34-43-53-32
Loss on assets held for sale-0-10  
Debt modification costs-1-10  
Restructuring expense-3-2-19-26-7
Asset impairments-60   
Amortization of acquired intangible assets-11-36-61-97 
Strategic advisory costs-120   
Home Office-36-31-26-33-40
CEO transition costs  0-6 
Deferred revenue adjustment  0-9 
Gain on sale of assets  130 
Total34221716877118


Assets by Segment
$ Mil20222021202020192018
Walden1,686    
Medical and Veterinary708773   
Home Office3421,248416266292
Chamberlain293484   
Discontinued Operations 580  61
Financial Services  580582457
Medical and Healthcare  1,232815989
Business and Law   580547
Total3,0293,0852,2292,2432,345


Price Behavior

Price Behavior
Market Price$117.89 
Market Cap ($ Bil)4.0 
First Trading Date06/28/1991 
Distance from 52W High-23.7% 
   50 Days200 Days
DMA Price$120.40$116.45
DMA Trendindeterminateup
Distance from DMA-2.1%1.2%
 3M1YR
Volatility46.4%47.5%
Downside Capture9.9730.62
Upside Capture40.3116.99
Correlation (SPY)5.0%7.5%
CVSA Betas & Captures as of 5/31/2026

 1M2M3M6M1Y3Y
Beta1.541.150.440.440.460.79
Up Beta3.031.050.610.491.190.94
Down Beta3.102.660.13-0.120.120.84
Up Capture54%53%70%80%10%55%
Bmk +ve Days13283667141432
Stock +ve Days6183267135424
Down Capture76%185%8%39%48%78%
Bmk -ve Days7132757109318
Stock -ve Days14233157115321

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CVSA
CVSA-3.3%47.4%0.10-
Sector ETF (XLY)12.8%18.3%0.522.3%
Equity (SPY)27.2%12.4%1.667.5%
Gold (GLD)25.8%27.4%0.821.6%
Commodities (DBC)23.3%18.9%0.98-5.3%
Real Estate (VNQ)13.6%13.5%0.6910.5%
Bitcoin (BTCUSD)-37.7%42.4%-1.00-0.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CVSA
CVSA25.5%42.3%0.67-
Sector ETF (XLY)7.6%23.8%0.2725.0%
Equity (SPY)13.8%17.1%0.6327.7%
Gold (GLD)17.6%18.2%0.781.4%
Commodities (DBC)7.8%19.4%0.304.3%
Real Estate (VNQ)2.5%18.8%0.0422.7%
Bitcoin (BTCUSD)12.1%54.2%0.4212.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with CVSA
CVSA21.7%39.5%0.63-
Sector ETF (XLY)12.7%22.1%0.5333.0%
Equity (SPY)15.4%18.0%0.7335.5%
Gold (GLD)12.8%16.1%0.66-0.7%
Commodities (DBC)6.2%18.0%0.2711.2%
Real Estate (VNQ)5.6%20.7%0.2328.0%
Bitcoin (BTCUSD)60.7%66.8%1.008.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date5292026
Short Interest: Shares Quantity1.5 Mil
Short Interest: % Change Since 51520260.9%
Average Daily Volume0.3 Mil
Days-to-Cover Short Interest5.3 days
Basic Shares Quantity34.3 Mil
Short % of Basic Shares4.5%

Earnings Returns History

Updated 6/10/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/7/202614.3%8.1%8.0%
1/28/2026-7.0%-13.3%-15.5%
10/30/2025-30.9%-32.9%-33.5%
8/7/20252.2%7.6%14.3%
5/8/202517.6%12.5%4.8%
1/30/20254.6%6.6%-2.5%
10/29/20249.5%8.4%21.0%
8/6/2024-8.6%-2.1%-3.6%
...
SUMMARY STATS   
# Positive151614
# Negative9810
Median Positive9.4%7.7%10.2%
Median Negative-7.1%-9.2%-10.7%
Max Positive17.6%25.7%33.7%
Max Negative-30.9%-32.9%-33.5%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/7/202614.3%8.1%8.0%
1/28/2026-7.0%-13.3%-15.5%
10/30/2025-30.9%-32.9%-33.5%
8/7/20252.2%7.6%14.3%
5/8/202517.6%12.5%4.8%
1/30/20254.6%6.6%-2.5%
10/29/20249.5%8.4%21.0%
8/6/2024-8.6%-2.1%-3.6%
5/2/202414.7%22.1%25.2%
1/31/20245.9%2.3%3.8%
10/26/202315.8%25.7%33.7%
8/10/20230.4%-3.7%1.0%
5/2/202311.2%7.7%9.0%
2/2/202313.4%1.9%0.2%
11/3/20221.0%2.5%-5.7%
8/11/2022-0.5%1.6%4.2%
5/5/20229.4%9.1%22.5%
2/8/2022-14.1%-17.6%-16.5%
11/3/2021-16.1%-6.6%-19.6%
8/19/20213.9%6.4%11.4%
4/29/2021-7.1%-9.5%-1.5%
2/2/2021-3.1%2.2%-5.9%
11/5/20207.7%15.0%20.8%
8/18/2020-5.8%-9.0%-26.9%
SUMMARY STATS   
# Positive151614
# Negative9810
Median Positive9.4%7.7%10.2%
Median Negative-7.1%-9.2%-10.7%
Max Positive17.6%25.7%33.7%
Max Negative-30.9%-32.9%-33.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/07/202610-Q
12/31/202501/28/202610-Q
09/30/202510/30/202510-Q
06/30/202508/07/202510-K
03/31/202505/08/202510-Q
12/31/202401/30/202510-Q
09/30/202410/29/202410-Q
06/30/202408/06/202410-K
03/31/202405/02/202410-Q
12/31/202301/30/202410-Q
09/30/202310/26/202310-Q
06/30/202308/10/202310-K
03/31/202305/02/202310-Q
12/31/202202/02/202310-Q
09/30/202211/03/202210-Q
06/30/202208/11/202210-K
Collapse to Preview
Report DateFiling DateFiling
03/31/202605/07/202610-Q
12/31/202501/28/202610-Q
09/30/202510/30/202510-Q
06/30/202508/07/202510-K
03/31/202505/08/202510-Q
12/31/202401/30/202510-Q
09/30/202410/29/202410-Q
06/30/202408/06/202410-K
03/31/202405/02/202410-Q
12/31/202301/30/202410-Q
09/30/202310/26/202310-Q
06/30/202308/10/202310-K
03/31/202305/02/202310-Q
12/31/202202/02/202310-Q
09/30/202211/03/202210-Q
06/30/202208/11/202210-K
03/31/202205/05/202210-Q
12/31/202102/08/202210-Q
09/30/202111/03/202110-Q
06/30/202108/19/202110-K
03/31/202104/29/202110-Q
12/31/202002/02/202110-Q
09/30/202011/05/202010-Q
06/30/202008/18/202010-K
03/31/202005/05/202010-Q
12/31/201902/04/202010-Q
09/30/201910/30/201910-Q
06/30/201908/28/201910-K

Recent Forward Guidance

Updated 5/31/2026

Latest: Q3 2026 Earnings Reported 5/7/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue1.93 Bil1.94 Bil1.95 Bil0.9% RaisedGuidance: 1.92 Bil for 2026
2026 Adjusted EPS7.958.058.151.9% RaisedGuidance: 7.9 for 2026
2026 Revenue Growth8.0%8.5%9.0%   
2026 Adjusted EPS Growth19.0%20.5%22.0%   

Prior: Q2 2026 Earnings Reported 1/28/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue1.90 Bil1.92 Bil1.94 Bil0 AffirmedGuidance: 1.92 Bil for 2026
2026 Adjusted EPS7.87.981.9% RaisedGuidance: 7.75 for 2026

Insider Activity

Updated 6/12/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Beard,, Stephen WChairman & CEODirectSell6122026130.782,529330,75555,457,029Form
2Beard,, Stephen WChairman & CEODirectSell6122026130.142,762359,44355,512,267Form
3Phelan, Robert JChief Financial OfficerDirectSell5122026126.2110,0001,262,0647,043,074Form
4Beck, Douglas GSVP, GC, Corp. Sec & ISSDirectSell5122026127.039,6151,221,3814,847,288Form
5Cox, Karen SuePresident, Chamberlain Univ.DirectSell5122026124.502,000249,0003,933,702Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Beard,, Stephen WChairman & CEODirectSell6122026130.782,529330,75555,457,029Form
2Beard,, Stephen WChairman & CEODirectSell6122026130.142,762359,44355,512,267Form
3Phelan, Robert JChief Financial OfficerDirectSell5122026126.2110,0001,262,0647,043,074Form
4Beck, Douglas GSVP, GC, Corp. Sec & ISSDirectSell5122026127.039,6151,221,3814,847,288Form
5Cox, Karen SuePresident, Chamberlain Univ.DirectSell5122026124.502,000249,0003,933,702Form
6Beard,, Stephen WChairman & CEODirectSell5122026131.2515,8742,083,50956,350,020Form
7Malafronte, Michael W Michael W Malafronte 2016 Gift TrustBuy3122026100.948,890897,3412,563,326Form
8Malafronte, Michael W DirectBuy3122026100.8611,8411,194,33911,418,388Form
9Malafronte, Michael W Michael W Malafronte 2016 Gift TrustBuy3122026100.8615,3051,543,7341,664,772Form
10Malafronte, Michael W Michael W Malafronte 2016 Gift TrustBuy305202697.971,200117,564117,564Form
11Phelan, Kenneth J DirectBuy1105202598.2950849,9311,846,181Form
12Malafronte, Michael W DirectBuy1104202591.851,00091,8509,225,873Form
13Wardell, Lisa W DirectSell8292025132.3825,4773,372,6635,752,074Form
14Wardell, Lisa W DirectSell8272025135.2218,3922,486,8899,320,155Form
15Gangadharan, ManjunathVP, Chief Accounting OfficerDirectSell8272025135.67944128,072664,919Form
16Wardell, Lisa W DirectSell8252025132.9012,9001,714,46512,290,591Form
17Burke, William W DirectSell6062025128.352,291294,0481,202,373Form
Core Cache Last Updated: 6/16/2026